CA Patent

CA3233305A1 — Solid forms of fxr agonists

Assigned to Gilead Sciences Inc · Expires 2020-08-27 · 6y expired

What this patent protects

Disclosed herein are novel solid forms of FXR agonists, and more specifically a solid form of tromethamine salt of a compound, having the following formula: Further disclosed are pharmaceutical compositions containing one or more of the solid forms disclosed herein, as well as me…

USPTO Abstract

Disclosed herein are novel solid forms of FXR agonists, and more specifically a solid form of tromethamine salt of a compound, having the following formula: Further disclosed are pharmaceutical compositions containing one or more of the solid forms disclosed herein, as well as methods of using the solid forms in the treatment of conditions mediated by FXR. The disclosure also relates to methods for obtaining such solid forms.

Drugs covered by this patent

Patent Metadata

Patent number
CA3233305A1
Jurisdiction
CA
Classification
—
Expires
2020-08-27
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.